Immunogenic Cell Death in Cancer: From Benchside Research to Bedside
Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2016 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (145 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546699604498 |
---|---|
ctrlnum |
(CKB)3710000001048138 (oapen)https://directory.doabooks.org/handle/20.500.12854/49986 (EXLCZ)993710000001048138 |
collection |
bib_alma |
record_format |
marc |
spelling |
Abhishek D. Garg auth Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Immunogenic Cell Death in Cancer Frontiers Media SA 2016 1 electronic resource (145 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality. English cancer immunology immunocontexture prognostic/predictive biomarker immunosurveillance DAMPs patient immunology cancer immunotherapy Cell Death anti-tumor immunity danger signals Apoptosis necroptosis 2-88919-838-3 Patrizia Agostinis auth |
language |
English |
format |
eBook |
author |
Abhishek D. Garg |
spellingShingle |
Abhishek D. Garg Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Frontiers Research Topics |
author_facet |
Abhishek D. Garg Patrizia Agostinis |
author_variant |
a d g adg |
author2 |
Patrizia Agostinis |
author2_variant |
p a pa |
author_sort |
Abhishek D. Garg |
title |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_full |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_fullStr |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_full_unstemmed |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_auth |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_alt |
Immunogenic Cell Death in Cancer |
title_new |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
title_sort |
immunogenic cell death in cancer: from benchside research to bedside |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2016 |
physical |
1 electronic resource (145 p.) |
isbn |
2-88919-838-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT abhishekdgarg immunogeniccelldeathincancerfrombenchsideresearchtobedside AT patriziaagostinis immunogeniccelldeathincancerfrombenchsideresearchtobedside AT abhishekdgarg immunogeniccelldeathincancer AT patriziaagostinis immunogeniccelldeathincancer |
status_str |
n |
ids_txt_mv |
(CKB)3710000001048138 (oapen)https://directory.doabooks.org/handle/20.500.12854/49986 (EXLCZ)993710000001048138 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Immunogenic Cell Death in Cancer: From Benchside Research to Bedside |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796651979760467968 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04250nam-a2200433z--4500</leader><controlfield tag="001">993546699604498</controlfield><controlfield tag="005">20231214133029.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2016 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000001048138</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49986</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000001048138</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Abhishek D. Garg</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunogenic Cell Death in Cancer: From Benchside Research to Bedside</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Immunogenic Cell Death in Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (145 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunocontexture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic/predictive biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunosurveillance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DAMPs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patient immunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cell Death</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-tumor immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">danger signals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">necroptosis</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-838-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patrizia Agostinis</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:39:52 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-02-11 15:57:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338292440004498&Force_direct=true</subfield><subfield code="Z">5338292440004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338292440004498</subfield></datafield></record></collection> |